Paul Bieniasz

Last updated
Paul Bieniasz
Born(1968-01-02)January 2, 1968
Alma mater
Spouse Theodora Hatziioannou
Awards
  • Elizabeth Glaser Award, 2003
  • Eli Lilly and Company Research Award, 2010
  • K.T. Jeang Retrovirology Prize, 2015
Scientific career
Institutions

Paul Darren Bieniasz is a British-American virologist whose main area of research is HIV/AIDS. He is currently a professor of retrovirology at the Rockefeller University. He received the 2015 KT Jeang Retrovirology Prize [1] and the 2010 Eli Lilly and Company Research Award. [2] Bieniasz has been a Howard Hughes Medical Institute investigator since 2008. [3]

Contents

Early life and education

Paul Bieniasz was born in Norfolk in 1968. His grandfather moved to England from Poland at the outbreak of the World War II. Bieniasz grew up in Lincolnshire where he attended The King's School, Grantham. [4] In 1990, he graduated from the University of Bath with a B.Sc. in biochemistry. Later, he joined the laboratory of Myra McClure at St. Mary’s Hospital Medical School, at the Imperial College London University of London. He completed his doctoral thesis in 1996 on foamy viruses entitled "Foamy viruses: Phylogeny, replication and exploitation for gene transfer." [5]

Career

In 1996, Paul Bieniasz joined Bryan Cullen's lab at Duke University as a postdoctoral associate. At Duke, Bieniasz studied several aspects of the HIV-1 life cycle, including the determinants of specificity in the viral envelope with the cellular receptor CCR5 [6] and HIV-1 Tat interaction with host factors. [7] Bieniasz started his own independent lab in 1999 at the Aaron Diamond AIDS Research Center and Rockefeller University in New York. Initially he worked on understanding how later steps of viral infection, such as assembly and budding, were inhibited in rodent cells. [8] This interest in viral budding came to define Bieniasz's career. Bieniasz showed that the retroviral protein Gag assembles at the plasma membrane, [9] recruiting the viral genome [10] by hijacking a specialized cellular protein complex involved in membrane vesicle trafficking, the ESCRT complex. [11] Together with his wife and colleague, Theodora Hatziioannou, they identified several host-specific factors that restrict replication of HIV-1 in macaques. Tetherin, a potent antiviral factor, was also discovered in his lab and shown to be counteracted by the HIV-1 accessory protein Vpu. [12] Subsequently, another inhibitor of HIV-1 replication was discovered in his lab, Mx2, a cellular protein shown to inhibit post-entry steps of the HIV-1 infection. [13] In recent years, Paul Bieniasz's group has focused on viral RNA interactions with cellular proteins; in particular, his group showed that APOBEC3G is recruited to virions by interaction with the viral RNA, [14] [15] and that CG-depletion of HIV-1 genomes is a mechanism to evade the antiviral, RNA-binding protein ZAP. [16] Bieniasz acted as Chair of the NIH AIDS Molecular and Cellular Biology study section from 2004 to 2009 and served on the NCI Board of Scientific Counselors from 2010 to 2014.

Related Research Articles

<span class="mw-page-title-main">Retrovirus</span> Family of viruses

A retrovirus is a type of virus that inserts a DNA copy of its RNA genome into the DNA of a host cell that it invades, thus changing the genome of that cell. After invading a host cell's cytoplasm, the virus uses its own reverse transcriptase enzyme to produce DNA from its RNA genome, the reverse of the usual pattern, thus retro (backwards). The new DNA is then incorporated into the host cell genome by an integrase enzyme, at which point the retroviral DNA is referred to as a provirus. The host cell then treats the viral DNA as part of its own genome, transcribing and translating the viral genes along with the cell's own genes, producing the proteins required to assemble new copies of the virus. Many retroviruses cause serious diseases in humans, other mammals, and birds.

<span class="mw-page-title-main">Antiviral drug</span> Medication used to treat a viral infection

Antiviral drugs are a class of medication used for treating viral infections. Most antivirals target specific viruses, while a broad-spectrum antiviral is effective against a wide range of viruses. Antiviral drugs are one class of antimicrobials, a larger group which also includes antibiotic, antifungal and antiparasitic drugs, or antiviral drugs based on monoclonal antibodies. Most antivirals are considered relatively harmless to the host, and therefore can be used to treat infections. They should be distinguished from virucides, which are not medication but deactivate or destroy virus particles, either inside or outside the body. Natural virucides are produced by some plants such as eucalyptus and Australian tea trees.

<span class="mw-page-title-main">Defective interfering particle</span>

Defective interfering particles (DIPs), also known as defective interfering viruses, are spontaneously generated virus mutants in which a critical portion of the particle's genome has been lost due to defective replication or non-homologous recombination. The mechanism of their formation is presumed to be as a result of template-switching during replication of the viral genome, although non-replicative mechanisms involving direct ligation of genomic RNA fragments have also been proposed. DIPs are derived from and associated with their parent virus, and particles are classed as DIPs if they are rendered non-infectious due to at least one essential gene of the virus being lost or severely damaged as a result of the defection. A DIP can usually still penetrate host cells, but requires another fully functional virus particle to co-infect a cell with it, in order to provide the lost factors.

<span class="mw-page-title-main">Hepatitis C virus</span> Species of virus

The hepatitis C virus (HCV) is a small, enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. The hepatitis C virus is the cause of hepatitis C and some cancers such as liver cancer and lymphomas in humans.

<span class="mw-page-title-main">Kaposi's sarcoma-associated herpesvirus</span> Species of virus

Kaposi's sarcoma-associated herpesvirus (KSHV) is the ninth known human herpesvirus; its formal name according to the International Committee on Taxonomy of Viruses (ICTV) is Human gammaherpesvirus 8, or HHV-8 in short. Like other herpesviruses, its informal names are used interchangeably with its formal ICTV name. This virus causes Kaposi's sarcoma, a cancer commonly occurring in AIDS patients, as well as primary effusion lymphoma, HHV-8-associated multicentric Castleman's disease and KSHV inflammatory cytokine syndrome. It is one of seven currently known human cancer viruses, or oncoviruses. Even after many years since the discovery of KSHV/HHV8, there is no known cure for KSHV associated tumorigenesis.

<span class="mw-page-title-main">TRIM5alpha</span>

Tripartite motif-containing protein 5 also known as RING finger protein 88 is a protein that in humans is encoded by the TRIM5 gene. The alpha isoform of this protein, TRIM5α, is a retrovirus restriction factor, which mediates a species-specific early block to retrovirus infection.

<span class="mw-page-title-main">APOBEC3G</span> Protein and coding gene in humans

APOBEC3G is a human enzyme encoded by the APOBEC3G gene that belongs to the APOBEC superfamily of proteins. This family of proteins has been suggested to play an important role in innate anti-viral immunity. APOBEC3G belongs to the family of cytidine deaminases that catalyze the deamination of cytidine to uridine in the single stranded DNA substrate. The C-terminal domain of A3G renders catalytic activity, several NMR and crystal structures explain the substrate specificity and catalytic activity.

<span class="mw-page-title-main">Long terminal repeat</span> DNA sequence

A long terminal repeat (LTR) is a pair of identical sequences of DNA, several hundred base pairs long, which occur in eukaryotic genomes on either end of a series of genes or pseudogenes that form a retrotransposon or an endogenous retrovirus or a retroviral provirus. All retroviral genomes are flanked by LTRs, while there are some retrotransposons without LTRs. Typically, an element flanked by a pair of LTRs will encode a reverse transcriptase and an integrase, allowing the element to be copied and inserted at a different location of the genome. Copies of such an LTR-flanked element can often be found hundreds or thousands of times in a genome. LTR retrotransposons comprise about 8% of the human genome.

NSP1 (NS53), the product of rotavirus gene 5, is a nonstructural RNA-binding protein that contains a cysteine-rich region and is a component of early replication intermediates. RNA-folding predictions suggest that this region of the NSP1 mRNA can interact with itself, producing a stem-loop structure similar to that found near the 5'-terminus of the NSP1 mRNA.

<span class="mw-page-title-main">APOBEC3F</span> Protein-coding gene in the species Homo sapiens

DNA dC->dU-editing enzyme APOBEC-3F is a protein that in humans is encoded by the APOBEC3F gene.

<span class="mw-page-title-main">APOBEC3C</span> Protein-coding gene in humans

DNA dC->dU-editing enzyme APOBEC-3C is a protein that in humans is encoded by the APOBEC3C gene.

Intrinsic immunity refers to a set of cellular-based anti-viral defense mechanisms, notably genetically encoded proteins which specifically target eukaryotic retroviruses. Unlike adaptive and innate immunity effectors, intrinsic immune proteins are usually expressed at a constant level, allowing a viral infection to be halted quickly. Intrinsic antiviral immunity refers to a form of innate immunity that directly restricts viral replication and assembly, thereby rendering a cell non-permissive to a specific class or species of viruses. Intrinsic immunity is conferred by restriction factors preexisting in certain cell types, although these factors can be further induced by virus infection. Intrinsic viral restriction factors recognize specific viral components, but unlike other pattern recognition receptors that inhibit viral infection indirectly by inducing interferons and other antiviral molecules, intrinsic antiviral factors block viral replication immediately and directly.

<span class="mw-page-title-main">Tetherin</span> Mammalian protein found in Homo sapiens

Tetherin, also known as bone marrow stromal antigen 2, is a lipid raft associated protein that in humans is encoded by the BST2 gene. In addition, tetherin has been designated as CD317. This protein is constitutively expressed in mature B cells, plasma cells and plasmacytoid dendritic cells, and in many other cells, it is only expressed as a response to stimuli from IFN pathway.

<span class="mw-page-title-main">Virus</span> Infectious agent that replicates in cells

A virus is a submicroscopic infectious agent that replicates only inside the living cells of an organism. Viruses infect all life forms, from animals and plants to microorganisms, including bacteria and archaea. Viruses are found in almost every ecosystem on Earth and are the most numerous type of biological entity. Since Dmitri Ivanovsky's 1892 article describing a non-bacterial pathogen infecting tobacco plants and the discovery of the tobacco mosaic virus by Martinus Beijerinck in 1898, more than 11,000 of the millions of virus species have been described in detail. The study of viruses is known as virology, a subspeciality of microbiology.

Tat (HIV)

In molecular biology, Tat is a protein that is encoded for by the tat gene in HIV-1. Tat is a regulatory protein that drastically enhances the efficiency of viral transcription. Tat stands for "Trans-Activator of Transcription". The protein consists of between 86 and 101 amino acids depending on the subtype. Tat vastly increases the level of transcription of the HIV dsDNA. Before Tat is present, a small number of RNA transcripts will be made, which allow the Tat protein to be produced. Tat then binds to cellular factors and mediates their phosphorylation, resulting in increased transcription of all HIV genes, providing a positive feedback cycle. This in turn allows HIV to have an explosive response once a threshold amount of Tat is produced, a useful tool for defeating the body's response.

<span class="mw-page-title-main">Antiviral protein</span>

Antiviral proteins are proteins that are induced by human or animal cells to interfere with viral replication. These proteins are isolated to inhibit the virus from replicating in a host's cells and stop it from spreading to other cells. The Pokeweed antiviral protein and the Zinc-Finger antiviral protein are two major antiviral proteins that have undergone several tests for viruses, including HIV and influenza.

<span class="mw-page-title-main">Viperin</span>

Radical S-adenosyl methionine domain-containing protein 2 is a protein that in humans is encoded by the RSAD2 gene. RSAD2 is a multifunctional protein in viral processes that is an interferon stimulated gene. It has been reported that viperin could be induced by either IFN-dependent or IFN-independent pathways and certain viruses may use viperin to increase their infectivity.

<span class="mw-page-title-main">Host switch</span> Evolutionary change of the host specificity of a parasite or pathogen

In parasitology and epidemiology, a host switch is an evolutionary change of the host specificity of a parasite or pathogen. For example, the human immunodeficiency virus used to infect and circulate in non-human primates in West-central Africa, but switched to humans in the early 20th century.

HSV epigenetics is the epigenetic modification of herpes simplex virus (HSV) genetic code.

In the management of HIV/AIDS, HIV capsid inhibitors are antiretroviral medicines that target the capsid shell of the virus. Most current antiretroviral drugs used to treat HIV do not directly target the viral capsid. These have also been termed "Capsid-targeting Antivirals", "Capsid Effectors", and "Capsid Assembly Modulators (CAMs)". Because of this, drugs that specifically inhibit the HIV capsid are being developed in order to reduce the replication of HIV, and treat infections that have become resistant to current antiretroviral therapies.

References

  1. "Paul D. Bieniasz wins the KT Jeang Retrovirology prize 2015 - On Biology". On Biology. 2015-10-07. Retrieved 2018-05-31.
  2. "American Society for Microbiology honors Paul D. Bieniasz". EurekAlert!. American Society for Microbiology. 2 March 2010. Retrieved 10 December 2020.
  3. "Paul D. Bieniasz, PhD | HHMI.org". HHMI.org. Retrieved 2018-05-31.
  4. "Paul Bieniasz | This Week in Virology". December 2015.
  5. CSHL Leading Strand (2014-11-11), CSHL Keynote, Dr Paul Bieniasz, Aaron Diamond AIDS Research Center , retrieved 2018-05-31
  6. Bieniasz PD, Fridell RA, Aramori I, Ferguson SS, Caron MG, Cullen BR (May 1997). "HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor". The EMBO Journal. 16 (10): 2599–609. doi:10.1093/emboj/16.10.2599. PMC   1169871 . PMID   9184207.
  7. Bieniasz PD, Grdina TA, Bogerd HP, Cullen BR (December 1998). "Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat". The EMBO Journal. 17 (23): 7056–65. doi:10.1093/emboj/17.23.7056. PMC   1171053 . PMID   9843510.
  8. Bieniasz PD, Cullen BR (November 2000). "Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells". Journal of Virology. 74 (21): 9868–77. doi:10.1128/JVI.74.21.9868-9877.2000. PMC   102023 . PMID   11024113.
  9. Jouvenet N, Neil SJ, Bess C, Johnson MC, Virgen CA, Simon SM, Bieniasz PD (December 2006). "Plasma membrane is the site of productive HIV-1 particle assembly". PLOS Biology. 4 (12): e435. doi: 10.1371/journal.pbio.0040435 . PMC   1750931 . PMID   17147474.
  10. Jouvenet N, Simon SM, Bieniasz PD (November 2009). "Imaging the interaction of HIV-1 genomes and Gag during assembly of individual viral particles". Proceedings of the National Academy of Sciences of the United States of America. 106 (45): 19114–9. Bibcode:2009PNAS..10619114J. doi: 10.1073/pnas.0907364106 . PMC   2776408 . PMID   19861549.
  11. Jouvenet N, Zhadina M, Bieniasz PD, Simon SM (April 2011). "Dynamics of ESCRT protein recruitment during retroviral assembly". Nature Cell Biology. 13 (4): 394–401. doi:10.1038/ncb2207. PMC   3245320 . PMID   21394083.
  12. Neil SJ, Zang T, Bieniasz PD (January 2008). "Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu". Nature. 451 (7177): 425–30. Bibcode:2008Natur.451..425N. doi: 10.1038/nature06553 . PMID   18200009.
  13. Kane M, Yadav SS, Bitzegeio J, Kutluay SB, Zang T, Wilson SJ, Schoggins JW, Rice CM, Yamashita M, Hatziioannou T, Bieniasz PD (October 2013). "MX2 is an interferon-induced inhibitor of HIV-1 infection". Nature. 502 (7472): 563–6. Bibcode:2013Natur.502..563K. doi:10.1038/nature12653. PMC   3912734 . PMID   24121441.
  14. Zennou V, Perez-Caballero D, Göttlinger H, Bieniasz PD (November 2004). "APOBEC3G incorporation into human immunodeficiency virus type 1 particles". Journal of Virology. 78 (21): 12058–61. doi:10.1128/JVI.78.21.12058-12061.2004. PMC   523273 . PMID   15479846.
  15. York A, Kutluay SB, Errando M, Bieniasz PD (August 2016). "The RNA Binding Specificity of Human APOBEC3 Proteins Resembles That of HIV-1 Nucleocapsid". PLOS Pathogens. 12 (8): e1005833. doi: 10.1371/journal.ppat.1005833 . PMC   4991800 . PMID   27541140.
  16. Takata MA, Gonçalves-Carneiro D, Zang TM, Soll SJ, York A, Blanco-Melo D, Bieniasz PD (October 2017). "CG dinucleotide suppression enables antiviral defence targeting non-self RNA". Nature. 550 (7674): 124–127. Bibcode:2017Natur.550..124T. doi:10.1038/nature24039. PMC   6592701 . PMID   28953888.